H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Rezolute (RZLT) to $5 from $14 and keeps a Buy rating on the shares. The firm is “surprised and disappointed “by the negative results of the sunRIZE study, but it still sees a path forward. The analyst continues to see value in the shares and pushed out the launch of ersodetug in congenital hyperinsulinism from 2027 to 2028.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Rezolute downgraded to Hold from Buy at Craig-Hallum
- Rezolute price target lowered to $5 from $17 at BTIG
- Rezolute downgraded to Market Perform from Outperform at Citizens
- Rezolute downgraded to Neutral from Overweight at Cantor Fitzgerald
- Wedbush downgrades Rezolute to Neutral after congenital hyperinsulinism miss